AR056748A1 - Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco - Google Patents
Solucion de cloruro de sodio para reconstitucion o dilucion de farmacoInfo
- Publication number
- AR056748A1 AR056748A1 ARP060104769A ARP060104769A AR056748A1 AR 056748 A1 AR056748 A1 AR 056748A1 AR P060104769 A ARP060104769 A AR P060104769A AR P060104769 A ARP060104769 A AR P060104769A AR 056748 A1 AR056748 A1 AR 056748A1
- Authority
- AR
- Argentina
- Prior art keywords
- injection
- prevent
- reconstitution
- dilution
- hemolysis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invencion proporciona métodos para la preparacion de formulaciones farmacéuticas para inyeccion tal que en la inyeccion la formulacion no provoque la aglutinacion de eritrocitos, hemolisis, y/o contraccion de células. Para prevenir la aglutinacion, una formulacion farmacéutica preparada para inyeccion necesita tener una fuerza ionica suficiente. Para prevenir la hemolisis o la contraccion de células, una formulacion farmacéutica preparada para inyeccion necesita ser casi isotonica con respecto al plasma. La invencion proporciona métodos que preparan formulaciones farmacéuticas para inyeccion que tienen tanto la fuerza ionica suficiente para prevenir la aglutinacion y la tonicidad requerida para prevenir hemolisis o deshidratacion o contraccion de células significativas. Los métodos presentes involucran el uso de soluciones de cloruro de socio que son alredodor de 25 MM hasta alrededor de 150 mM para reconstitucion de tortas liofilizadas (u otras formulaciones farmacéuticas no líquidas) en solucion o para dilucion de soluciones de formulacion farmacéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73222105P | 2005-11-01 | 2005-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056748A1 true AR056748A1 (es) | 2007-10-24 |
Family
ID=37801586
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060104769A AR056748A1 (es) | 2005-11-01 | 2006-10-31 | Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco |
ARP180101902 AR112443A2 (es) | 2005-11-01 | 2018-07-06 | Un kit para reconstitución o dilución de un fármaco |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101902 AR112443A2 (es) | 2005-11-01 | 2018-07-06 | Un kit para reconstitución o dilución de un fármaco |
Country Status (31)
Country | Link |
---|---|
US (4) | US20070135343A1 (es) |
EP (3) | EP3593790A1 (es) |
JP (1) | JP5555425B2 (es) |
KR (2) | KR101126670B1 (es) |
CN (1) | CN101351190B (es) |
AR (2) | AR056748A1 (es) |
AU (1) | AU2006308921C1 (es) |
BR (1) | BRPI0618133A2 (es) |
CA (1) | CA2626531C (es) |
CR (1) | CR9958A (es) |
DK (2) | DK3225233T3 (es) |
EC (1) | ECSP088485A (es) |
ES (2) | ES2749574T3 (es) |
FI (1) | FI1942868T4 (es) |
FR (1) | FR20C1005I1 (es) |
GT (1) | GT200800037A (es) |
HK (1) | HK1245090B (es) |
HU (4) | HUE045421T2 (es) |
IL (1) | IL190843A (es) |
LU (1) | LUC00035I2 (es) |
MY (1) | MY184364A (es) |
NO (1) | NO347263B1 (es) |
NZ (1) | NZ567685A (es) |
PE (3) | PE20110803A1 (es) |
PL (2) | PL3225233T3 (es) |
PT (2) | PT1942868T (es) |
RU (1) | RU2432157C2 (es) |
SI (2) | SI3225233T1 (es) |
TW (1) | TWI480063B (es) |
UA (1) | UA97234C2 (es) |
WO (1) | WO2007053533A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20110803A1 (es) | 2005-11-01 | 2011-11-07 | Wyeth Corp | Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
US8431011B2 (en) | 2008-01-31 | 2013-04-30 | Abbott Diabetes Care Inc. | Method for automatically and rapidly distinguishing between control and sample solutions in a biosensor strip |
CA2780554C (en) * | 2009-11-17 | 2017-08-15 | Ipsen Pharma S.A.S. | Formulation for hgh and rhigf-1 combination |
US10634741B2 (en) | 2009-12-04 | 2020-04-28 | Endomagnetics Ltd. | Magnetic probe apparatus |
US9427186B2 (en) | 2009-12-04 | 2016-08-30 | Endomagnetics Ltd. | Magnetic probe apparatus |
HUE046670T2 (hu) | 2010-01-15 | 2020-03-30 | Kirin Amgen Inc | Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére |
NZ602685A (en) * | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
EA037095B1 (ru) | 2010-07-09 | 2021-02-05 | Биовератив Терапьютикс Инк. | Способ лечения гемофилии в и эпизодов кровотечения |
WO2014052490A1 (en) * | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
JP6351639B2 (ja) | 2013-03-11 | 2018-07-04 | エンドマグネティクス リミテッド | リンパ節検出のための低浸透圧溶液 |
US9234877B2 (en) | 2013-03-13 | 2016-01-12 | Endomagnetics Ltd. | Magnetic detector |
US9239314B2 (en) | 2013-03-13 | 2016-01-19 | Endomagnetics Ltd. | Magnetic detector |
TWI683666B (zh) * | 2013-03-15 | 2020-02-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
FR3005420B1 (fr) * | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
KR102385372B1 (ko) * | 2014-03-24 | 2022-04-11 | 바이오버라티브 테라퓨틱스 인크. | 동결건조된 ix 인자 제형 |
US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
GB2536703B (en) * | 2015-03-27 | 2020-12-02 | Ge Healthcare Bio Sciences Ab | Method for baseline correction in a chromatogram |
EP3081942A1 (en) * | 2015-04-17 | 2016-10-19 | Roche Diagniostics GmbH | Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample |
EP3302338B1 (en) | 2015-06-04 | 2020-09-30 | Endomagnetics Ltd. | Marker materials and forms for magnetic marker localization |
US10124021B2 (en) * | 2016-12-23 | 2018-11-13 | Andrew L. Gostine | Intravenous fluid |
JP7110360B2 (ja) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ,エルエルシー | 凍結乾燥方法 |
JP7495426B2 (ja) | 2019-03-14 | 2024-06-04 | テルモ ビーシーティー バイオテクノロジーズ,エルエルシー | 凍結乾燥容器用充填治具、システム及び使用方法 |
US12036187B2 (en) * | 2019-05-01 | 2024-07-16 | Southwest Research Institute | Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote |
IL272145A (en) * | 2020-01-20 | 2021-07-29 | Stem Cell Medicine Ltd | Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue |
AU2021322623A1 (en) * | 2020-08-03 | 2023-03-02 | Transluminal Systems, Llc | Devices and methods for trans-arterial osmotic embolization of pathological tissue |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3717708A (en) * | 1968-10-24 | 1973-02-20 | Cutter Lab | Blood coagulation complex |
US4364861A (en) | 1980-05-27 | 1982-12-21 | Cutter Laboratories, Inc. | Blood-coagulation-promoting products and methods of preparing them |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
JP5149470B2 (ja) | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | 新規のアルブミンを含有していない第viii因子処方物 |
US20010031721A1 (en) * | 1999-05-05 | 2001-10-18 | Chandra Webb | Highly concentrated, lyophilized, and liquid factor IX formulations |
US6875432B2 (en) * | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
KR20150138427A (ko) * | 2003-12-19 | 2015-12-09 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 안정화된 조성물 |
JP2007526329A (ja) * | 2004-03-04 | 2007-09-13 | ワイス | 賦形剤の結晶化を改善するための凍結乾燥法 |
PE20110803A1 (es) | 2005-11-01 | 2011-11-07 | Wyeth Corp | Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco |
-
2006
- 2006-10-27 PE PE2011000653A patent/PE20110803A1/es not_active Application Discontinuation
- 2006-10-27 KR KR1020087013252A patent/KR101126670B1/ko active IP Right Grant
- 2006-10-27 SI SI200632348T patent/SI3225233T1/sl unknown
- 2006-10-27 EP EP19189599.4A patent/EP3593790A1/en not_active Withdrawn
- 2006-10-27 ES ES17166616T patent/ES2749574T3/es active Active
- 2006-10-27 UA UAA200807432A patent/UA97234C2/ru unknown
- 2006-10-27 PE PE2006001318A patent/PE20070714A1/es not_active Application Discontinuation
- 2006-10-27 JP JP2008538945A patent/JP5555425B2/ja active Active
- 2006-10-27 NO NO20082180A patent/NO347263B1/no unknown
- 2006-10-27 TW TW095139724A patent/TWI480063B/zh active
- 2006-10-27 KR KR1020117027131A patent/KR20110128957A/ko not_active Application Discontinuation
- 2006-10-27 SI SI200632172T patent/SI1942868T2/sl unknown
- 2006-10-27 HU HUE17166616A patent/HUE045421T2/hu unknown
- 2006-10-27 CN CN2006800400807A patent/CN101351190B/zh active Active
- 2006-10-27 EP EP17166616.7A patent/EP3225233B1/en not_active Revoked
- 2006-10-27 NZ NZ567685A patent/NZ567685A/en unknown
- 2006-10-27 DK DK17166616.7T patent/DK3225233T3/da active
- 2006-10-27 US US11/589,002 patent/US20070135343A1/en not_active Abandoned
- 2006-10-27 WO PCT/US2006/042258 patent/WO2007053533A2/en active Application Filing
- 2006-10-27 ES ES06827036T patent/ES2627684T5/es active Active
- 2006-10-27 BR BRPI0618133-3A patent/BRPI0618133A2/pt not_active Application Discontinuation
- 2006-10-27 RU RU2008119514/15A patent/RU2432157C2/ru active
- 2006-10-27 PT PT68270362T patent/PT1942868T/pt unknown
- 2006-10-27 PL PL17166616T patent/PL3225233T3/pl unknown
- 2006-10-27 DK DK06827036.2T patent/DK1942868T5/da active
- 2006-10-27 CA CA2626531A patent/CA2626531C/en active Active
- 2006-10-27 PL PL06827036.2T patent/PL1942868T5/pl unknown
- 2006-10-27 HU HUE06827036A patent/HUE033949T2/hu unknown
- 2006-10-27 PT PT171666167T patent/PT3225233T/pt unknown
- 2006-10-27 PE PE2015001729A patent/PE20151284A1/es not_active Application Discontinuation
- 2006-10-27 MY MYPI20081347A patent/MY184364A/en unknown
- 2006-10-27 AU AU2006308921A patent/AU2006308921C1/en active Active
- 2006-10-27 EP EP06827036.2A patent/EP1942868B2/en active Active
- 2006-10-31 AR ARP060104769A patent/AR056748A1/es not_active Application Discontinuation
-
2008
- 2008-04-14 IL IL190843A patent/IL190843A/en active IP Right Grant
- 2008-04-17 GT GT200800037A patent/GT200800037A/es unknown
- 2008-05-07 CR CR9958A patent/CR9958A/es not_active Application Discontinuation
- 2008-05-30 EC EC2008008485A patent/ECSP088485A/es unknown
-
2016
- 2016-10-07 US US15/288,860 patent/US20170021022A1/en not_active Abandoned
-
2017
- 2017-09-25 LU LU00035C patent/LUC00035I2/fr unknown
- 2017-09-27 HU HUS1700035C patent/HUS1700035I1/hu unknown
-
2018
- 2018-04-04 HK HK18104477.4A patent/HK1245090B/zh unknown
- 2018-07-06 AR ARP180101902 patent/AR112443A2/es not_active Application Discontinuation
-
2019
- 2019-12-20 US US16/723,563 patent/US20200138952A1/en not_active Abandoned
-
2020
- 2020-01-31 HU HUS2000003C patent/HUS2000003I1/hu unknown
- 2020-02-10 FR FR20C1005C patent/FR20C1005I1/fr active Active
- 2020-07-14 US US16/946,998 patent/US20200338199A1/en not_active Abandoned
-
2023
- 2023-03-17 FI FIEP06827036.2T patent/FI1942868T4/fi active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056748A1 (es) | Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco | |
AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
AR039688A1 (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
DE69906084D1 (de) | Ibuprofen enthaltende schnelllösliche zusammensetzungen mit analgetischer wirkung | |
PE20070492A1 (es) | Forma cristalina delta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen | |
AR078885A2 (es) | Composiciones estabilizadas de proteinas que tienen un radical tiol libre. recipiente impermeable. metodo. | |
ATE316757T1 (de) | Cryokonservierung menschlicher roter blutzellen | |
EA199800563A1 (ru) | Антагонисты гормона, высвобождающего гонадотропин | |
AR033059A1 (es) | Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. | |
GT200600033A (es) | Formulaciones liquidas estabilizadas de polipeptido | |
AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
ECSP034613A (es) | Preparacion liofilizada de pantoprazol e inyeccion de pantoprazol | |
IS7394A (is) | Stöðugar lyfjasamsetningar | |
CY1106181T1 (el) | Φαρμακευτικος σχηματισμος ο οποιος πepιλαμβανει γλυκινη σαν ενα σταθepοποιητη | |
ATE226449T1 (de) | Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen | |
Liu et al. | Cytoprotective properties of novel nonpeptide calpain inhibitors in renal cells | |
ES2418459R1 (es) | Relacionando agregacion proteica con supervivencia de levadura | |
ME00088B (me) | Farmaceutski preparat i njegova priprema | |
BR112022025192A2 (pt) | Derivado de insulina asparte, e método de preparação para o mesmo e uso do mesmo | |
AR091707A1 (es) | Formulaciones estabilizadas de etanercept | |
DE69927845D1 (de) | Verwendung des vaskularen endothelialen wachstumsfaktors (vegf) | |
Pollanen et al. | An investigation of orienting mechanisms of the quantum Hall stripe phases | |
UY37260A (es) | Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón | |
TH125812B (th) | องค์ประกอบสารเสริมซึ่งประกอบรวมด้วยสารไอโซโทนิกที่ไม่เป็นไอออนิก | |
Tao et al. | THE FAUNA AND GE0GRAPHICAL DIVISI0N 0N GLIRES 0F GANSU PR0VINCE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |